Vazopro

Vazopro belongs to the pharmacotherapeutic group of cardiopreparations that stimulate contractions of the heart muscle. The international nonproprietary name - Meldonium, synonyms - Metonat, Milkardil, Mildrazin, Vazonat, Midolat, Cardionate, Celebis and others.

Indications of the vazopro

The drug Vazopro is prescribed for such pathologies as:

• chronic heart failure;
• cardiac ischemia;
• angina pectoris;
• myocardial infarction, including acute;
• subcompensated and decompensated circulatory disorders;
• discirculatory encephalopathy, including cerebral stroke;
• hemorrhage and thrombosis of the retina vessels;
• decrease in efficiency at physical overloads.

Vazopro is also used in the complex treatment of alcohol withdrawal.

Release form

Vazopro is available as a solution for injection in ampoules of 5 ml, as well as in capsules of 250 and 500 mg. 

Pharmacodynamics

Vazopro's cardiotonic action is provided by the active substance meldonium (methonate or 3-2,2,2-trimethylhydrazinium propionate dihydrate), which suppresses the synthesis of the amino acid L-carnitine, which transfers activated fatty acids through internal mitochondrial membranes. Thus, under conditions of hypoxia and ischemic stress, carnitine-dependent free radical oxidation of lipids in myocardial cells and their cleavage into neurotoxic cell-derived derivatives acylcarnitine and acyl coenzyme A.

Vasodilating effect of vasopro is due to the fact that a decrease in the level of L-carnitine activates the synthesis of a physiologically active substance of gamma-butyrobetaine. The drug stabilizes the balance of oxygen production and consumption by cells. In addition, the intensity of the splitting of glucose associated with the formation of ATP increases, and thus the energy supply of cells is optimized. Due to this, myocardial tone and its ability to contract significantly increase, as well as blood circulation in the ischemic focus, in the vessels of the brain and retina.

Pharmacokinetics

Biological availability Vazopro for oral intake is 78%, the maximum concentration in blood plasma is achieved on average after 2 hours. With parenteral use of the drug, bioavailability is 100%, and the maximum concentration in plasma is achieved immediately after injection. The half-life period ranges from 3 to 6 hours.

Metabolites formed in the process of drug transformation are eliminated by the kidneys - with urine. Their half-life is approximately 4.5 hours.

Dosing and administration

Vazopro in the form of a solution for injection is administered intravenously: in cardiovascular pathologies - 5-10 ml per day; with violations of cerebral circulation - 5 ml once a day; at a syndrome of an alcoholic abstinence - on 0,5 ml twice a day (a minimum within 7 days). With the pathology of the retinal vessels, the drug is injected through the skin of the lower eyelid (parabulbar) - 0.5 ml per day, treatment course -10 days.

With chronic heart failure and chronic circulatory disorders, Vazopro capsules are taken, the dose and duration of the drug intake are prescribed by the doctor.

[2]

Use of the vazopro during pregnancy

The use of vasoproro during pregnancy is also contraindicated, since no clinical studies have been conducted regarding the safety of this drug for the mother and fetus.

Contraindications

Vazopro is contraindicated to use with increased intracranial pressure associated with a violation of outflow of venous blood or the presence of primary and secondary brain tumors, as well as with organic lesions of the central nervous system caused by cerebral vascular pathologies, craniocerebral trauma, exposure to toxic substances,

This drug is not used in the treatment of patients younger than 18 years. For chronic liver and kidney diseases, the drug should be used with caution.

Side effects of the vazopro

The use of vasoprof can be accompanied by side effects in the form of headache, dizziness, cardiac arrhythmia, instability of blood pressure, dry mouth, nausea, diarrhea. In rare cases, general weakness, hyperemia and itching of the skin, hives, shortness of breath, dry cough, hyperhidrosis are possible.

[1]

Overdose

Information on cases of overdose Vasopro no.

Interactions with other drugs

In the complex treatment of cardiovascular insufficiency and coronary heart disease, vasopro can be combined with preparations of other pharmacological groups: cardiac glycosides, antiarrhythmic, antihypoxic and antiplatelet agents, antianginal drugs for arresting coronary insufficiency attacks, and diuretic drugs.

Simultaneous intake of vasoprof can enhance the action of nitroglycerin, calcium channel blockers (nifedipine), beta-blockers (metoprolol, bisoprolol, carvedilol), antihypertensive drugs and drugs that relax the smooth muscles of peripheral blood vessels (vasodilators).

[3]

Storage conditions

Storage conditions: at a temperature not higher than + 25 ° C, in a place protected from light.

Shelf life

Shelf life - 24 months.